Cargando…
Perhexiline treatment improves toxic effects of β‐adrenergic receptor stimulation in experimental peripartum cardiomyopathy
AIMS: Peripartum cardiomyopathy (PPCM) is a pregnancy‐associated cardiomyopathy that occurs in previously heart‐healthy women towards the end of pregnancy or in the first months after delivery and is characterized by heart failure due to systolic dysfunction. The clinical course of PPCM differs betw...
Autores principales: | Pfeffer, Tobias J., List, Manuel, Müller, Julia H., Scherr, Michaela, Bauersachs, Johann, Hilfiker‐Kleiner, Denise, Ricke‐Hoch, Melanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318439/ https://www.ncbi.nlm.nih.gov/pubmed/34002539 http://dx.doi.org/10.1002/ehf2.13412 |
Ejemplares similares
-
Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy
por: Nonhoff, Justus, et al.
Publicado: (2017) -
Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy
por: Pfeffer, Tobias J., et al.
Publicado: (2022) -
Increased Cancer Prevalence in Peripartum Cardiomyopathy
por: Pfeffer, Tobias J., et al.
Publicado: (2019) -
High prevalence of reduced fertility and use of assisted reproductive technology in a German cohort of patients with peripartum cardiomyopathy
por: Pfeffer, Tobias J., et al.
Publicado: (2022) -
Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy
por: Stapel, Britta, et al.
Publicado: (2017)